A January 2026 meta-analysis found pomegranate products were associated with small but statistically significant reductions in blood pressure and inflammatory markers tied to cardiovascular risk.
By yourNEWS Media Newsroom,
A new review of randomized controlled trials has found that pomegranate supplementation may offer modest cardiovascular benefits, including lower blood pressure and reduced markers of inflammation.
The meta-analysis, published in January 2026, examined 33 randomized controlled trials involving 1,490 participants between the ages of 20 and 75. Researchers reviewed studies that tested pomegranate juice, extract capsules, peel extracts and seed oil over periods ranging from five days to 48 weeks.
The review found that pomegranate supplementation reduced systolic blood pressure by 3.52 mmHg and diastolic blood pressure by 1.50 mmHg. It also lowered interleukin-6, or IL-6, and intercellular adhesion molecule 1, or ICAM-1, two inflammatory markers associated with vascular inflammation and cardiovascular disease risk.
Researchers searched PubMed/MEDLINE, Web of Science, SCOPUS and Embase from the launch of each database through January 2026. The trials included pomegranate products in several forms, with juice doses ranging from 50 mL to 500 mL per day and standardized extract capsules ranging from 450 mg to 3,000 mg per day.
Although the blood pressure reductions were not large, the findings may be meaningful when viewed across broader populations. Even small sustained decreases in systolic blood pressure can be associated with lower cardiovascular risk when maintained over time.
The review pointed to punicalagin, pomegranate’s primary ellagitannin, as a likely driver of the effects. Research indicates the compound may act in a way similar to ACE inhibitor medications by reducing production of angiotensin II, a hormone that narrows blood vessels. Punicalagin may also support vasodilation and inhibit the NF-κB signaling pathway, which is involved in the production of pro-inflammatory cytokines.
The reductions in IL-6 and ICAM-1 suggest pomegranate may influence more than blood pressure alone. Both markers are tied to inflammation in the lining of blood vessels and are associated with early processes involved in atherosclerosis.
Pomegranate has long been valued in ancient Greek, Egyptian and Persian traditions, but modern research has increasingly examined it as a functional food with potential cardiovascular effects. The new review adds to evidence that foods containing concentrated polyphenols may help support heart health when included as part of a broader healthy diet.
The findings come as cardiovascular disease remains a leading global cause of death and hypertension affects a large share of adults. Dietary strategies that produce even modest improvements in blood pressure may have public health importance, particularly when used alongside established lifestyle measures.
The included trials varied widely in dosage, duration and participant characteristics. Some studies reported effects within two weeks, though stronger findings generally appeared in trials lasting more than eight weeks. Researchers said longer-term studies are needed to determine whether the observed improvements persist and whether they translate into fewer cardiovascular events.
The review also noted possible side effects and drug interactions. Some participants reported mild digestive symptoms, including upset stomach, nausea and constipation. People taking blood pressure medications or other drugs, including ACE inhibitors, statins and antidepressants, should consult a healthcare provider before using pomegranate products regularly.
The review does not establish pomegranate as a substitute for prescribed treatment. Instead, it suggests pomegranate juice or supplements may serve as a complementary dietary option for supporting cardiovascular health.
For people already focused on heart-healthy eating, the findings point to pomegranate as a potentially useful addition alongside foods such as berries, olive oil and leafy greens. The evidence indicates the benefits are modest, but consistent enough to support further study.
Source: Natural News